https://www.selleckchem.com/pr....oducts/elsubrutinib.
Scenario analyses were performed by adjusting time horizon, TFR parameters, costs, and utilities. Second-line nilotinib resulted in greater time spent in TFR (0.91 life-years), increased quality-adjusted life-years (QALYs) (1.89), increased life-years (2.16), and decreased per-patient costs (-38,760€). Therefore, nilotinib was strongly dominant compared with dasatinib in the base-case analysis. Nilotinib remained strongly dominant in most scenario analyses including shorter time horizon, exclusion of TFR, and varying TKI drug costs
Like
Comment
Share
